Improved Anti-Emetic Efficacy of 5-HT3Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter

Association of ABCB1 Polymorphisms With the Efficacy of Ondansetron in Chemotherapy-induced Nausea and Vomiting

(2014) Hui He et al.   CLINICAL THERAPEUTICS

Association of ABCB1 Polymorphisms with the Antiemetic Efficacy of Granisetron plus Dexamethasone in Breast Cancer Patients

(2013) Daiki Tsuji et al.   Drug Metabolism and Pharmacokinetics

Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy

(2011) D. A. Perwitasari et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting

(2010) E. M. Choi et al.   ANAESTHESIA

A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function

(2009) King Leung Fung et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers

(2009) Jörn Lötsch et al.   Pharmacogenetics and Genomics

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

(2009) Paul J. Hesketh et al.   SUPPORTIVE CARE IN CANCER

Meta-Analysis of the Effect of MDR1 C3435T Polymorphism on Cyclosporine Pharmacokinetics

(2008) Zhi-Ping Jiang et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Evidence-Based Recommendations for Cancer Nausea and Vomiting

(2008) Arash Naeim et al.   JOURNAL OF CLINICAL ONCOLOGY